4 unchanged sentences
Additional risks and uncertainties not presently known to us or that we currently believe are immaterial may also materially adversely affect our business, results of operations, financial condition and future growth prospects, and our stock price.
−Removed: There have been no material changes to the risk factors set forth in Item 1A.
−Removed: “Risk Factors” of our 2023 Annual Report on Form 10-K filed on February 21, 2024 .
+Added: The following risk factors applicable to the Company as set forth in Item 1A.
+Added: Risk Factors of our 2024 Annual Report on Form 10-K filed on February 20, 2025 , has been added or updated.
+Added: Tariff policies and potential countermeasures could increase our costs and disrupt our global supply chain, which could negatively impact the results of our operations.
+Added: In April 2025, the U.S.
+Added: began enacting the imposition of widespread and substantial tariffs on imports, with plans for additional tariffs to potentially be adopted in the future.
+Added: We are unable to predict what additional actions, if any, may ultimately be taken by the U.S.
+Added: or other governments with respect to tariffs or trade relations, which products may be subject to such actions (including subject to U.S.
+Added: export control restrictions), or what actions may be taken by any other countries in retaliation, or the impact, if any, that any such policy changes could have on our business.
+Added: The potential resultant impact of the imposition of these or any other new or increased tariffs on import markets could have an adverse effect on Globus’ results of operations, cash flow and financial condition.
+Added: Risks Relating to the Nevro Merger
+Added: Integrating the Nevro business into Globus may be more difficult, costly or time-consuming than expected and Globus may fail to realize the anticipated benefits of the Nevro Merger, which may adversely affect our business results and negatively affect the value of our common stock.
+Added: We have incurred and expect to incur non-recurring costs associated with the acquisition of Nevro, as well as transaction fees and other costs related to the Nevro Merger.
+Added: Such costs include, among others, legal, accounting, investment banking and consulting fees.
+Added: The success of the Nevro Merger will depend on, among other things, our ability to realize the anticipated benefits, synergies and efficiencies from integrating the Nevro business into Globus.
+Added: If we are not able to successfully integrate Nevro’s business into Globus within the anticipated time frame, or at all, the anticipated synergies, efficiencies and other benefits of the Nevro Merger may not be realized fully, or at all, or may take longer to realize than expected.
+Added: In addition, Globus may incur additional or unexpected costs in order to realize these benefits.
+Added: Failure to achieve the expected synergies could significantly reduce the expected benefits associated with the Nevro Merger.
+Added: An inability to realize the full extent of the anticipated benefits of the Nevro Merger, as well as any delays encountered in the integration process, could have an adverse effect upon the revenues, level of expenses and operating results of Globus, which may adversely affect the value of our common stock.
+Added: The Company may also incur restructuring and integration costs in connection with the Nevro Merger.
+Added: There are processes, policies, procedures, operations, technologies and systems that must be integrated in connection with the Nevro Merger and the integration of Nevro’s business into Globus.
+Added: Although Globus expects that the elimination of duplicative costs, strategic benefits and additional income, as well as the realization of other efficiencies related to the integration of the businesses, may offset incremental transaction, merger-related and restructuring costs over time, any net benefit may not be achieved in the near term or at all.
+Added: Globus has assumed that certain expenses would be incurred in connection with the Nevro Merger, there are many factors beyond Globus’s control that could affect the total amount or the timing of the integration and implementation expenses.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.